Royal Bank Of Canada Cybin Inc. Transaction History

Royal Bank Of Canada

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.26 - $0.46 $3,607 - $6,382	-13,874 Reduced 56.5%	10,680 $2,000
Q1 2024 Nov 05, 2024	BUY	$0.3 - $0.46 $4,162 - $6,382	13,874 Added 129.91%	24,554 $10,000
Q1 2024 May 15, 2024	BUY	$0.3 - $0.46 $5,058 - $7,756	16,863 Added 219.26%	24,554 $10,000
Q4 2023 Feb 14, 2024	SELL	$0.38 - $0.65 $63 - $107	-166 Reduced 2.11%	7,691 $3,000
Q3 2023 Nov 14, 2023	SELL	$0.29 - $0.63 $690 - $1,500	-2,382 Reduced 23.26%	7,857 $4,000
Q2 2023 Aug 14, 2023	BUY	$0.23 - $0.39 $230 - $390	1,000 Added 10.82%	10,239 $3,000
Q1 2023 May 15, 2023	SELL	$0.3 - $0.56 $30,000 - $56,000	-100,000 Reduced 91.54%	9,239 $3,000
Q3 2022 Nov 14, 2022	BUY	$0.48 - $1.11 $47,326 - $109,441	98,596 Added 926.39%	109,239 $52,000
Q2 2022 Aug 15, 2022	BUY	$0.41 - $0.88 $2,136 - $4,586	5,212 Added 95.97%	10,643 $6,000
Q1 2022 May 16, 2022	BUY	$0.74 - $1.22 $2,024 - $3,337	2,736 Added 101.52%	5,431 $5,000
Q4 2021 Feb 14, 2022	SELL	$1.13 - $2.31 $6,101 - $12,474	-5,400 Reduced 66.71%	2,695 $4,000
Q3 2021 Nov 15, 2021	BUY	$1.83 - $3.18 $14,813 - $25,742	8,095 New	8,095 $18,000

185K

Ticker CYBN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 166,120,000
Market Cap $2.07B
Description
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to t...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.